Table 2.
Proportion of patients showing metabolic comorbidities in the clinical trials, according to the experimental drug vs. placebo.
| Author | Drug | Type 2 diabetes mellitus |
Arterial hypertension |
Dyslipidaemia |
|||
|---|---|---|---|---|---|---|---|
| Drug | Placebo | Drug | Placebo | Drug | Placebo | ||
| Neuschwander-Tetri, 2014 | Obeticholic acid | 53% | 52% | 62% | 60% | 62% | 61% |
| Friedman, 2018 | Cenicriviroc | 57% | 44% | Not reported | 48% | 49% | |
| Ratziu, 2016 | Elafibranor | 42% | 36% | 62% | 47% | 49% | 54% |
| Armstrong, 2016 | Liraglutide | 35% | 31% | 58% | 54% | 35% | 27% |
| Loomba, 2018 | Selonsertib | 66% | 80% | Not reported | Not reported | ||
| Sanyal, 2018 | Pegbelfermin | 33% | 42% | Not reported | 25% | 31% | |
| Harrison, 2018 | NGM282 | 61% | 63% | 64% | 78% | 54% | 30% |
| Traussnigg, 2019 | norUDCA | 6% | 16% | 39% | 41% | Not reported | |
| Loomba, 2018 | GS-0976 | 65% | 58% | Not reported | Not reported | ||
| Harrison, 2020 | Emricasan | 52% | 49% | Not reported | 56% | 61% | |